Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 plus rituximab in first-line follicular lymphoma
2025-522777-10-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of CN201 and rituximab in follicular lymphoma (FL) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of participants who experience an adverse event, Number of participants who discontinue study treatment due to an adverse event and 3 more. Planned start Jun 2026; status: authorised.
02
Drugs
CN201rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2025-522777-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522777-10-00.